文献类型：期刊文献

英文题名：Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma

作者：Hao, Xiangyong;Li, Zihan;Su, Xin[1,2];Li, Jian[1,2];Ye, Youbao[1,2];Wang, Cailiu[1,2];Xu, Xiao[1,2];Song, Hao[2];Song, Baoling[2];Lan, Xiang;Luo, Tian

第一作者：Su, Xin;Hao, Xiangyong;苏祥

通信作者：Hao, XY[1];Lan, X[2];Luo, T[3]

机构：[1]Gansu Prov Hosp, Dept Gen Surg, Lanzhou, Peoples R China;[2]Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou, Peoples R China

第一机构：Gansu Prov Hosp, Dept Gen Surg, Lanzhou, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Gen Surg, 204 Donggang West Rd, Lanzhou 730000, Peoples R China;[2]corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Chongqing 400016, Peoples R China;[3]corresponding author), Gansu Prov Hosp, Inst Clin Res & Translat Med, 204 Donggang West Rd, Lanzhou 730000, Peoples R China.

年份：2025

卷号：17

外文期刊名：THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

收录：;Scopus(收录号：2-s2.0-105014199450);WOS:【SCI-EXPANDED(收录号:WOS:001553841400001)】；

基金：The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Natural Science Foundation of Gansu Province (Grant No.: 23JRRA1313), Natural Science Foundation for Young Scientists and the Science and Technology Planning Project of Gansu Province (Grant No.: 18JR3RA058), Gansu Province Youth Innovative Talents Project (Grant No.: 2021LQGR15), Health Industry Scientific Research Program of Gansu Province (Grant No.: GSWSKY2020-06), and Research Projects of Gansu Provincial Hospital (Grant Nos.: 19SYPYB-7, 18GSSY3-1).

语种：英文

外文关键词：biomarkers; hepatocellular carcinoma; lenvatinib; predict

摘要：Hepatocellular carcinoma (HCC) is a highly lethal disease that exhibits a rising global incidence, and most HCC patients are at an advanced stage at the time of diagnosis. Although lenvatinib has become the first-line option for HCC and its overall survival is not inferior to sorafenib, not all HCC patients could derive benefits from lenvatinib. Therefore, it was urgent to predict which group of HCC patients could derive benefits from lenvatinib and monitor its therapeutic effectiveness during treatment. This review summarized various biomarkers that could be used for prediction of lenvatinib response, including 7 biomarkers that are applied in clinical practice, 11 biomarkers that are applied in clinical practice, and 6 biomarkers that are under exploratory stage. By conducting this first comprehensive analysis of predictive biomarkers for lenvatinib in HCC patients, this review aims to help doctors to assess the response of lenvatinib treatment more accurately and, thus, develop more effective individualized treatment plans.